Peptides TRIZ Cases

Novel antitumoral compounds of formula I enhance cytotoxic activity against cancer cells.

Oxalimidic acid warheads enable selective binding to target proteins while minimizing off-target conjugation and immunogenicity risks.

Bicyclic peptide ligands inhibit carbonic anhydrase IX and membrane type 1 metalloprotease with high affinity.

Sprayable cell penetrating peptide complexes deliver nucleic acids into plant cells without tissue damage or genotype dependency.

Polynucleotide sequences from Rhodosporidium and Rhodotorula enable strong gene expression in fungal species.

Removing stable positive charges from near-infrared fluorophores improves cellular uptake and detection sensitivity for microbial pathogens.

Sequential pyrolysis, protease treatment, and membrane separation reduce protein contamination in yeast mannoprotein extraction.

Combining oral octreotide with dopamine agonists or SERMs maintains reliable IGF-1 levels while eliminating inconvenient injectable SRL dosing schedules.

Sulfated AMPS co-monomers increase peptide loading in NIPAm nanoparticles, enabling targeted cartilage diffusion and cytokine suppression.

NR4A1 PROTAC degraders recruit E3 ligases to degrade the target protein, inhibiting tumor growth while rejuvenating anti-tumor immunity.

Polypeptide fragment reagents detect Mycobacterium infections while avoiding cross-reactivity with BCG-vaccinated animals and environmental mycobacteria.

An alpha radiolabeled gastrin analogue uses modified amino acid sequences to achieve selective tumor accumulation.

Co-expressing PrdH facilitates PrdA self-cleavage and pyruvoyl group introduction, resolving activation reliability issues in enzyme production.

Dual-targeting cyclic peptides inhibit HIF dimer assembly by binding PAS-B domains, overcoming incomplete hypoxia blockade from single-isoform strategies.

Cyclic DKCLA peptides competitively inhibit calreticulin binding, blocking nitric oxide signaling and preventing bone destruction in rheumatoid arthritis.

Detect anti-CXC chemokine receptor antibodies in patient samples to diagnose autoimmune diseases and acute graft-versus-host disease with high sensitivity.

Targeted molecular imaging probes bind to cancer cell surface markers, enabling non-invasive detection of metastasized breast cancer cells.

In vivo dendritic cell targeting eliminates ex vivo processing, reducing treatment time while inducing tumor regression.

A hybrid promoter merges CHEF1 regulatory elements with a CMV sequence to drive recombinant protein expression in host cells.

Macrocyclic compounds bind PD-1 to block immune evasion, reversing suppression in cancer and infectious diseases.

Segmenting inhibitor units onto a composite scaffold improves binding strength and selectivity while managing molecular complexity.

Replacing toxic gadolinium with optimized manganese chelates eliminates nephrogenic systemic fibrosis risks while maintaining diagnostic image quality.

A tolerizing vector induces immunological tolerance to suppress host immune responses against dystrophin replacement, improving therapeutic efficacy.

Heterologous expression of the tomaymycin biosynthetic gene cluster in Streptomyces albus J1074 overcomes low native yields, achieving 338 mg/l production.

A co-polyisocyanopeptide hydrogel forms a 3D structure with controlled stiffness to support stable cell growth.

A self-replicating RNA liposome formulation produces sustained interleukin-12 expression within transduced cells.

A selective transport molecule uses a cleavable peptide linker to facilitate cellular uptake of cargo moieties.

Modular cyclic decapeptide framework reduces production costs and toxicity while maintaining integrin alpha v beta 3 targeting affinity.

VPC-70063 and VPC-70067 bind the Myc-Max DNA-binding domain to inhibit transcriptional activity.

Targeted mass spectrometry quantitates glycated CD59 peptides, replacing time-intensive hemoglobin assays with rapid clinical monitoring.